logo.jpg.jpg
ViaDerma, Inc. Provides Updates on Current Business Activities
June 24, 2021 05:00 ET | ViaDerma, Inc.
LOS ANGELES, June 24, 2021 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink: VDRM), is pleased to provide an update on current business activities. The Company has finalized a ten-year $12...
logo.jpg.jpg
ViaDerma, Inc. Announces Expansion of its Current Licensing Agreement and Provides Additional Company Updates
June 02, 2021 05:00 ET | ViaDerma, Inc.
LOS ANGELES, June 02, 2021 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink: VDRM), is pleased to announce they have expanded their current licensing agreement with a home health wound care...
logo.jpg.jpg
ViaDerma, Inc. Nearing Initial Order from Large Hospital Network
May 13, 2021 05:00 ET | ViaDerma, Inc.
LOS ANGELES, May 13, 2021 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink: VDRM), announced they are nearing the end of their discussions with a major healthcare network to finalize an...
logo.jpg.jpg
ViaDerma, Inc. Provides Preliminary Revenue Estimates and Highlights for its Record Breaking 1st Quarter
April 08, 2021 05:00 ET | ViaDerma, Inc.
LOS ANGELES, April 08, 2021 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink: VDRM), is pleased to provide an update of estimated sales and revenue numbers for the first quarter of 2021, as...
logo.jpg.jpg
ViaDerma, Inc. Announces the Payment of all Toxic Convertible Notes and Has Become Debt Free
March 16, 2021 05:00 ET | ViaDerma, Inc.
LOS ANGELES, March 16, 2021 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink: VDRM), is pleased to announce they have paid off all outstanding toxic convertible debt and the Company is now...
logo.jpg.jpg
ViaDerma Inc., Provides Review of 2020 and Looks Forward to 2021
January 13, 2021 05:00 ET | ViaDerma, Inc.
LOS ANGELES, Jan. 13, 2021 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink:VDRM), President and CEO, Dr. Christopher Otiko offers a review of 2020 and provides a summary of his...
Misonix.jpg
Misonix Announces the Second Largest U.S. Commercial Payer Has Provided Coverage for TheraSkin® to Treat All Lower Extremity Dermal Wounds Adding 32 Million New Covered Lives
December 18, 2020 10:14 ET | MISONIX, Inc.
FARMINGDALE, N.Y., Dec. 18, 2020 (GLOBE NEWSWIRE) -- 2020) – Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that...
GelSana Receives Pre-Seed Investment from Innosphere Ventures
November 30, 2020 12:22 ET | Innosphere Ventures
Golden and Fort Collins, CO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Innosphere Ventures, Colorado’s commercialization program and seed-stage venture capital fund, has announced their investment in...
APstem-Therapeutics.jpg
APstem Therapeutics Announces Successful FDA INTERACT Meeting Regarding AP-Skin-01, an “Off-the-Shelf” Allogeneic Stem Cell Product for the Treatment of Diabetic Ulcers
October 28, 2020 20:08 ET | APstem Therapeutics
Fremont, CA , Oct. 28, 2020 (GLOBE NEWSWIRE) -- APstem Therapeutics, Inc., a private biopharmaceutical company developing breakthrough stem cell therapies, today announced the completion of an...
misonix.jpg
Misonix Announces Results of New Large Real-World Studies That Further Prove the Clinical Effectiveness of TheraSkin
December 05, 2019 09:30 ET | MISONIX, Inc.
FARMINGDALE, N.Y., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and...